(MedPage Today) — The FDA will require earlier, additional MRI monitoring for Alzheimer’s disease patients taking lecanemab (Leqembi), an amyloid-directed treatment given by IV infusion, the agency said Thursday.
The agency called for the drug…
Source link : https://www.medpagetoday.com/neurology/alzheimersdisease/117218
Author :
Publish date : 2025-08-29 14:05:00
Copyright for syndicated content belongs to the linked Source.
